Home » Newsletters » BioWorld Science

BioWorld Science

April 24, 2009

View Archived Issues

Universita di Bologna patents novel AChE and BChE inhibitors

GlaxoSmithKline presents novel muscarinic M1 receptor agonists

Novel gonadotropin-releasing hormone receptor antagonists claimed by Kissei

Solvay describes cannabinoid CB1 receptor agonists for pain treatment

Novel beta2-adrenoceptor agonists described by Sepracor for the treatment of bronchoconstriction

In vitro and phase I data on silymarin in hepatitis C presented

Travatan and DuoTrav show comparable efficacy in patients with primary open-angle glaucoma

Dual inhibitors of PI3K and mTOR with in vivo antitumor activity reported by Piramed and Genentech

MK-7009 combined with peginterferon, ribavirin in phase IIa study

Combination of filibuvir and peginterferon alfa-2a/ribavirin evaluated in HCV patients

Haptoglobin level a biomarker for gemcitabine-related hematological toxicities

MK-2206: Development through phase I study described

Immutep commences phase I ImmuFact IMP-321 trial in pancreatic cancer

Tranzyme reports positive phase II TZP-101 results in gastroparesis

FDA approves phase II trial for Bryostatin in Alzheimer's disease

Sanaria initiates phase I whole-parasite malaria vaccine trial

Acorda resubmits NDA for Fampridine-SR for improved walking in MS

Revlimid receives positive final appraisal determination for NHS

The caspase inhibitor GS-9450 well tolerated in phase I trial in healthy individuals

Molecular Sensing and VIB enter agreement in Alzheimer's disease research

NovaBay enters into agreement with the Medical University of Innsbruck

European Commission approves Removab for malignant ascites

Addrenex and Sciele report results for second phase III Clonicel study in ADHD

Dr. Reddy's launches Redispar in India for SHPT due to chronic kidney disease

Takeda discontinues TAK-379 development for diabetes

Vion receives an FDA standard review classification for Onrigin NDA

deCODE grants Celera licenses to risk markers for heart attack, stroke and diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...